BCG-driven activation of the bladder cancer TME involves the NFKB/TNFA signaling pathway and IRFs/IFN pathway
BCG-driven activation of the bladder cancer TME involves the NFκB/TNFα signaling pathway and IRFs/IFN pathway. While the IRF/IFN pathway selectively induces the chemokines attracting the desirable effector cells, the NFκB/TNFα pathway enhances the induction of both the CTL-attracting cytokines, CCL5, CXCL9, CXCL10, and CXCL11, but also amplifies the undesirable COX2/PGE2/EP4 pathway, which orchestrates the induction, activation, and recruitment of MDSCs and Tregs, through chemokines such as CXCL8, CXCL12, and CCL22. The combination of BCG with COX2- or EP4 blockers can selectively augment the attraction of CTLs while neutralizing PGE2-dependent suppressive factors and Treg and MDSC attractants, suggesting its potential to augment effective anti-tumor immunity in response to BCG treatment
Publication
Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette–Guérin Immunotherapy of Bladder Cancer (2024) Omar M. Ibrahim, et al. Cells. 2024 Apr;13(8). Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | EP4 | EP4 | ncbigene_synonym | PTGER4 | 5734 |
| Homo sapiens | Primates | COX2 | COX2 | ncbigene_symbol | COX2 | 4513 |
| Homo sapiens | Primates | COX2 | COX2 | ncbigene_synonym | PTGS2 | 5743 |
| Homo sapiens | Primates | COX2 | COX2 | ncbigene_synonym | MTCO2P12 | 107075310 |
| Homo sapiens | Primates | TNFα | TNF | ncbigene_symbol | TNF | 7124 |
| Homo sapiens | Primates | NFKB | NFKB | ncbigene_synonym | NFKB1 | 4790 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | RELA | 5970 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | RELB | 5971 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | REL | 5966 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | NFKB2 | 4791 |
| Homo sapiens | Primates | CCL5 | CCL5 | ncbigene_symbol | CCL5 | 6352 |
| Homo sapiens | Primates | CXCL9 | CXCL9 | ncbigene_symbol | CXCL9 | 4283 |
| Homo sapiens | Primates | CXCL10 | CXCL10 | ncbigene_symbol | CXCL10 | 3627 |
| Homo sapiens | Primates | CXCL11 | CXCL11 | ncbigene_symbol | CXCL11 | 6373 |
| Homo sapiens | Primates | NIN | NIN | ncbigene_symbol | NIN | 51199 |
| Homo sapiens | Primates | CXCL8 | CXCL8 | ncbigene_symbol | CXCL8 | 3576 |
| Homo sapiens | Primates | CXCL12 | CXCL12 | ncbigene_symbol | CXCL12 | 6387 |
| Homo sapiens | Primates | CCL22 | CCL22 | ncbigene_symbol | CCL22 | 6367 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| BCG | BCG | (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid | chebi:41001 | |
| CXCL9 | CXCL9 | chebi:138154 | ||
| CXCL10 | CXCL10 | chebi:138157 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|